newsfilter
← Earnings
Earnings Releases·

10x Genomics — Third Quarter 2026 Earnings Summary

  • Revenue grew 1% year-over-year to $150.7 million in Q3 2026, while gross margin expanded to 75% from 67% and operating loss narrowed to $16.1 million from $32.2 million.
  • Full-year 2026 revenue guidance was raised to $625–$635 million, representing 4–6% organic growth over 2025 when excluding non-recurring litigation settlement gains.
  • Commercial shipments of the Atera platform commenced with strong early demand, and spatial consumables revenue rose 16% to $41.2 million, offsetting a decline in total instrument revenue.
  • The company maintains a strong liquidity position with $575.7 million in cash, equivalents, and marketable securities as of September 30, 2026.
Company
10X GENOMICS INC
Sector
Healthcare
Industry
Health Information Services